News
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.
As the S&P 500 reaches new highs amid optimism over trade deals and corporate earnings, investors are closely watching the tech sector, which continues to drive market momentum despite concerns about ...
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...
The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a ...
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Real Chemistry’s latest acquisition adds up to Greater Than One. | Greater Than One will retain its name and New York City headquarters as it moves under the Real Chemistry umbrella, and its employees ...
2d
Fintel on MSNTruist Securities Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy RecommendationFintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...
As the U.S. stock market continues to flirt with record highs, driven by strong earnings reports and investor optimism, the tech-heavy Nasdaq Composite stands out as a key player in this bullish trend ...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...
Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results